Loading
BIO-106 is an experimental antibody-drug conjugate from BiOneCure Therapeutics in phase 2 trials, aimed at TROP2.
BIO-106 is an antibody-drug conjugate developed by BiOneCure Therapeutics. Its target is TROP2 (the sponsor names Trop-2). The sponsor states: BIO-106 is a novel antibody-drug conjugate targeting the human trophoblast cell surface antigen 2 (Trop-2). ClinicalTrials.gov describes the intervention as: BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05320588, plans to enrol 332 participants with primary completion was scheduled for 2024-04 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
BIO-106 is a novel antibody-drug conjugate targeting the human trophoblast cell surface antigen 2 (Trop-2). Connects to TROP2.
1.BIO-106's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BIO-106" OR ABSTRACT:"BIO-106") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BIO-106, not a curated reading list.
Shares TROP2, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tag pipeline.